• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Epidemiology, Ventilation Management, and Outcomes in Invasively Ventilated Coronavirus Disease 2019 Patients: An Analysis of Four Observational Studies in Four Countries on Two Continents.2019冠状病毒病有创通气患者的流行病学、通气管理及预后:对来自两大洲四个国家的四项观察性研究的分析
Am J Trop Med Hyg. 2025 Jan 21;112(4):875-882. doi: 10.4269/ajtmh.24-0257. Print 2025 Apr 2.
2
Positioning for acute respiratory distress in hospitalised infants and children.急性呼吸窘迫患儿的体位摆放。
Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD003645. doi: 10.1002/14651858.CD003645.pub4.
3
Systemic corticosteroids for the treatment of COVID-19.全身性皮质类固醇治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD014963. doi: 10.1002/14651858.CD014963.
4
Recruitment manoeuvres for adults with acute respiratory distress syndrome receiving mechanical ventilation.接受机械通气的成人急性呼吸窘迫综合征的肺复张手法
Cochrane Database Syst Rev. 2016 Nov 17;11(11):CD006667. doi: 10.1002/14651858.CD006667.pub3.
5
Physical interventions to interrupt or reduce the spread of respiratory viruses.物理干预措施以阻断或减少呼吸道病毒的传播。
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
6
Early versus late tracheostomy in critically ill COVID-19 patients.危重症 COVID-19 患者的早期与晚期气管切开术。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD015532. doi: 10.1002/14651858.CD015532.
7
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
8
Early spontaneous breathing for acute respiratory distress syndrome in individuals with COVID-19.COVID-19 相关急性呼吸窘迫综合征患者的早期自主呼吸。
Cochrane Database Syst Rev. 2022 Jun 29;6(6):CD015077. doi: 10.1002/14651858.CD015077.
9
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
10
Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence.全身性皮质类固醇治疗 COVID-19:与公平相关的分析和证据更新。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD014963. doi: 10.1002/14651858.CD014963.pub2.

本文引用的文献

1
Epidemiology, ventilation management and outcomes of COVID-19 ARDS patients versus patients with ARDS due to pneumonia in the Pre-COVID era.COVID-19 相关 ARDS 患者与大流行前肺炎相关 ARDS 患者的流行病学、通气管理和结局比较。
Respir Res. 2024 Aug 17;25(1):312. doi: 10.1186/s12931-024-02910-2.
2
Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study.在 50 个国家的重症监护病房中进行机械通气撤离(WEAN SAFE):一项多中心、前瞻性、观察性队列研究。
Lancet Respir Med. 2023 May;11(5):465-476. doi: 10.1016/S2213-2600(22)00449-0. Epub 2023 Jan 21.
3
Risk factors and effect on mortality of superinfections in a newly established COVID-19 respiratory sub-intensive care unit at University Hospital in Rome.罗马大学医院新成立的 COVID-19 呼吸亚重症监护病房中,超级感染的危险因素及其对死亡率的影响。
BMC Pulm Med. 2023 Jan 20;23(1):30. doi: 10.1186/s12890-023-02315-9.
4
The Lancet Commission on lessons for the future from the COVID-19 pandemic.《柳叶刀》新冠疫情对未来的启示委员会
Lancet. 2022 Oct 8;400(10359):1224-1280. doi: 10.1016/S0140-6736(22)01585-9. Epub 2022 Sep 14.
5
Co-Infections and Superinfections in COVID-19 Critically Ill Patients Are Associated with CT Imaging Abnormalities and the Worst Outcomes.新型冠状病毒肺炎危重症患者的合并感染和二重感染与CT影像异常及最差预后相关。
Diagnostics (Basel). 2022 Jul 3;12(7):1617. doi: 10.3390/diagnostics12071617.
6
Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study.指导 COVID-19 危重症患者个体化类固醇治疗的主要候选变量:CIBERESUCICOVID 研究。
Intensive Care Med. 2022 Jul;48(7):850-864. doi: 10.1007/s00134-022-06726-w. Epub 2022 Jun 21.
7
Clinical characteristics, respiratory management, and determinants of oxygenation in COVID-19 ARDS: A prospective cohort study.COVID-19 相关急性呼吸窘迫综合征的临床特征、呼吸管理和氧合决定因素:一项前瞻性队列研究。
J Crit Care. 2022 Oct;71:154021. doi: 10.1016/j.jcrc.2022.154021. Epub 2022 Mar 26.
8
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.2019 年全球细菌对抗菌药物耐药性的负担:系统分析。
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
9
Geoeconomic variations in epidemiology, ventilation management, and outcomes in invasively ventilated intensive care unit patients without acute respiratory distress syndrome: a pooled analysis of four observational studies.四项观察性研究的 pooled 分析:无急性呼吸窘迫综合征的侵入性通气重症监护病房患者的流行病学、通气管理和结局的地缘经济学差异。
Lancet Glob Health. 2022 Feb;10(2):e227-e235. doi: 10.1016/S2214-109X(21)00485-X. Epub 2021 Dec 13.
10
Association of Time-Varying Intensity of Ventilation With Mortality in Patients With COVID-19 ARDS: Secondary Analysis of the PRoVENT-COVID Study.新型冠状病毒肺炎急性呼吸窘迫综合征患者随时间变化的通气强度与死亡率的关联:PRoVENT-COVID研究的二次分析
Front Med (Lausanne). 2021 Nov 18;8:725265. doi: 10.3389/fmed.2021.725265. eCollection 2021.

2019冠状病毒病有创通气患者的流行病学、通气管理及预后:对来自两大洲四个国家的四项观察性研究的分析

Epidemiology, Ventilation Management, and Outcomes in Invasively Ventilated Coronavirus Disease 2019 Patients: An Analysis of Four Observational Studies in Four Countries on Two Continents.

作者信息

Blok Siebe G, Pisani Luigi, Estenssoro Elisa, Ferreira Juliana Carvalho, Botta Michela, Motos Ana, Martin-Loeches Ignacio, Torres Antoni, Schultz Marcus J, Paulus Frederique, van Meenen David M P

机构信息

Department of Intensive Care, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Mahidol Oxford Tropical Medicine Research Unit (MORU), Mahidol University, Bangkok, Thailand.

出版信息

Am J Trop Med Hyg. 2025 Jan 21;112(4):875-882. doi: 10.4269/ajtmh.24-0257. Print 2025 Apr 2.

DOI:10.4269/ajtmh.24-0257
PMID:39842032
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11965764/
Abstract

Epidemiology, ventilator management, and outcomes in patients with acute respiratory distress syndrome (ARDS) because of coronavirus disease 2019 (COVID-19) have been described extensively but have never been compared between countries. We performed an individual patient data analysis of four observational studies to compare epidemiology, ventilator management, and outcomes. We used propensity score weighting to control for confounding factors. The analysis included 6,702 patients: 1,500 from Argentina, 844 from Brazil, 975 from the Netherlands, and 3,383 from Spain. There were substantial differences in baseline characteristics between countries. There were small differences in ventilation management. Intensive care unit mortality was higher in Argentina and Brazil compared with the Netherlands and Spain (59.6% and 56.6% versus 32.1% and 34.7%; P <0.001). The median number of days free from ventilation and alive at day 28 was equally low (0 [0-7], 0 [0-18], 1 [0-16], and 0 [0-16] days, respectively; P = 0.03), and the median number of days free from ventilation and alive at day 60 was higher in the Netherlands and Spain (0 [0-37], 0 [0-50], 33 [0-48], and 26 [0-48] days, respectively; P <0.001). Propensity score matching confirmed the outcome differences. Thus, the outcome of COVID-19 ARDS patients in Argentina and Brazil was substantially worse compared with that of patients in the Netherlands and Spain. It is unlikely that this results from differences in case mix or ventilation management.

摘要

关于2019冠状病毒病(COVID-19)所致急性呼吸窘迫综合征(ARDS)患者的流行病学、呼吸机管理及预后情况已有大量描述,但各国之间从未进行过比较。我们对四项观察性研究进行了个体患者数据分析,以比较流行病学、呼吸机管理及预后情况。我们使用倾向评分加权法来控制混杂因素。该分析纳入了6702例患者:1500例来自阿根廷,844例来自巴西,975例来自荷兰,3383例来自西班牙。各国之间的基线特征存在显著差异。通气管理方面存在细微差异。与荷兰和西班牙相比,阿根廷和巴西重症监护病房的死亡率更高(分别为59.6%和56.6%,而荷兰和西班牙为32.1%和34.7%;P<0.001)。第28天无通气且存活的天数中位数同样较低(分别为0[0 - 7]天、0[0 - 18]天、1[0 - 16]天和0[0 - 16]天;P = 0.03),而第60天无通气且存活的天数中位数在荷兰和西班牙更高(分别为0[0 - 37]天、0[0 - 50]天、33[0 - 48]天和26[0 - 48]天;P<0.001)。倾向评分匹配证实了预后差异。因此,与荷兰和西班牙的患者相比,阿根廷和巴西COVID-19 ARDS患者的预后明显更差。这不太可能是由于病例组合或通气管理的差异所致。